Stroke Patients Develop Antibodies That React With Components of N-Methyl-D-Aspartate Receptor Subunit 1 in Proportion to Lesion Size [Clinical Sciences]

Conclusions— Antibodies that bind recombinant GluN1-S2 peptides (but not the intact GluN1 protein) develop transiently in patients after stroke in proportion to infarct size, suggesting that these antibodies are raised secondarily to neuronal damage. The anti–GluN1-S2 antibodies may provide useful information about the presence and severity of cerebral infarction. This will require confirmation in larger studies.

http://stroke.ahajournals.org/cgi/content/short/44/8/2212?rss=1

Source: Stroke - July 22, 2013 Category: Neurology Authors: Kalev-Zylinska, M. L., Symes, W., Little, K. C. E., Sun, P., Wen, D., Qiao, L., Young, D., During, M. J., Barber, P. A. Tags: Ischemic biology - basic studies, Other diagnostic testing Clinical Sciences Source Type: research